^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Excerpt:
...Positive FOLR1 expression per central laboratory testing 5....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.

Published date:
05/25/2023
Excerpt:
Endpoint...ORR (95% CI)...37.5% (21.1, 56.3)...These dose expansion data confirm activity of luvelta at starting doses ranging from 4.3-5.2 mg/kg in recurrent OC with FolRα expression as low as TPS>25% and supports further clinical study in this population.
DOI:
10.1200/JCO.2023.41.16_suppl.5508
Trial ID: